Ubs Group Ag Cogent Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 115,495 shares of COGT stock, worth $936,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares

115,495

Previous 126,539 8.73%

Holding current value

$936,664

Previous $1.07 Million 16.98%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$8.24 - $11.48 $91,002 - $126,785	-11,044 Reduced 8.73%	115,495 $1.25 Million
Q2 2024 Aug 13, 2024	SELL	$6.01 - $9.04 $1.83 Million - $2.75 Million	-304,466 Reduced 70.64%	126,539 $1.07 Million
Q1 2024 May 13, 2024	BUY	$4.38 - $9.02 $891,759 - $1.84 Million	203,598 Added 89.53%	431,005 $2.9 Million
Q4 2023 Feb 09, 2024	BUY	$4.06 - $10.08 $602,231 - $1.5 Million	148,333 Added 187.59%	227,407 $1.34 Million
Q3 2023 Nov 09, 2023	SELL	$9.69 - $13.34 $32,955 - $45,369	-3,401 Reduced 4.12%	79,074 $770,000
Q2 2023 Aug 11, 2023	SELL	$9.85 - $13.24 $103,178 - $138,689	-10,475 Reduced 11.27%	82,475 $976,000
Q1 2023 May 12, 2023	SELL	$10.04 - $15.5 $1.25 Million - $1.92 Million	-124,134 Reduced 57.18%	92,950 $1 Million
Q4 2022 Feb 08, 2023	BUY	$10.65 - $14.84 $1.96 Million - $2.74 Million	184,452 Added 565.25%	217,084 $2.51 Million
Q3 2022 Nov 10, 2022	BUY	$9.39 - $16.99 $301,259 - $545,090	32,083 Added 5843.9%	32,632 $487,000
Q2 2022 Aug 10, 2022	BUY	$3.92 - $9.73 $509 - $1,264	130 Added 31.03%	549 $5,000
Q1 2022 May 16, 2022	BUY	$5.31 - $8.7 $2,224 - $3,645	419 New	419 $3,000
Q4 2021 Feb 14, 2022	SELL	$7.51 - $10.81 $1,937 - $2,788	-258 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.99 - $9.14 $1,545 - $2,358	258 New	258 $2,000

Others Institutions Holding COGT

# of Institutions

172

Shares Held

113M

Call Options Held

56.7K

Put Options Held

40.4K

View Full List

About Cogent Biosciences, Inc.

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $533M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

More about COGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account